Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Pancreatic Adenocarcinoma, Version 2.2012

(2017) Margaret A. Tempero et al.   Journal of the National Comprehensive Cancer Network

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model

(2015) Samer Bazzi et al.   IMMUNOBIOLOGY

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

(2015) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

(2015) Manuel Hidalgo et al.   PANCREATOLOGY

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system

(2015) Yago Pico de Coaña et al.   TRENDS IN MOLECULAR MEDICINE

Prognostic factors related with survival in patients with pancreatic adenocarcinoma

(2014) Ahmet Bilici   WORLD JOURNAL OF GASTROENTEROLOGY

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy

(2013) Michael Haas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The immune network in pancreatic cancer development and progression

(2013) S M Wörmann et al.   ONCOGENE

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) T. Seufferlein et al.   ANNALS OF ONCOLOGY

Immunotherapy updates in pancreatic cancer: are we there yet?

(2012) Krishna Soujanya Gunturu et al.   Therapeutic Advances in Medical Oncology

An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma

(2011) J. Stebbing et al.   ANNALS OF ONCOLOGY

Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy

(2011) Daniel W. Fowler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

(2010) Giuseppe Colucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

(2009) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY